ubmslateCN-logo-ubm

CN Mobile Logo

Topics:

Genitourinary Cancers

Genitourinary Cancers

Patients with RCC had greater postsurgical decreases in kidney function compared with patients with upper tract urothelial carcinoma.

New NCCN guidelines regarding genomic profiling will likely yield important opportunities to improve the care of patients with advanced bladder cancer.

A new study has found a series of potential microRNA biomarkers that could predict tyrosine kinase inhibitor response in RCC patients.

In this paper, we review the use of serum tumor markers in risk assignment and response evaluation; the treatment of previously untreated and relapsing patients; the role of surgical resection of residual disease, including retroperitoneal node dissection; and the importance of clinical trials for addressing unanswered questions and testing new therapies.

Both African-American and Caucasian patients with advanced RCC have seen improved survival with targeted therapies, though African-Americans still experience survival disadvantages.

A randomized phase III trial found that a hypofractionated radiotherapy regimen was not superior to, but generally equivalent to a conventional radiotherapy scheme in men with localized prostate cancer.

In this video we discuss the continuation of nivolumab after tumor progression in patients with advanced renal cell carcinoma in the CheckMate 025 trial.

Pages

Subscribe to Genitourinary Cancers on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.